December 21, 2018
Dr. Reddy's Laboratories Inc. issued a voluntary recall for two additional lots of clopidogrel tablets, USP, 300 mg (NDC 55111-671-31), because the drug failed to meet dissolution specifications during 18-month testing, according to the December 19, 2018, US Food and Drug Administration (FDA) Enforcement Report.
The recall includes 4404 30-count blister packs from lots T700423 (Exp. 8/19) and T800310 (Exp. 3/20). The product was distributed throughout the United States.
Dr. Reddy's Laboratories issued the recall December 10, 2018. On December 11, 2018, the FDA designated the recall Class II, signaling use of the affected drugs may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.
Clopidogrel is a prescription blood thinner used to prevent stroke, heart attack, and other heart problems.
For more Pharmacy Learning Network articles, visit the homepage